NGNE Logo

Neurogene Inc. (NGNE) 

NASDAQ$15.85
Market Cap
$332.53M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
93 of 924
Rank in Industry
69 of 527

NGNE Insider Trading Activity

NGNE Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$2,720,023375
Sells
$76,247125

Related Transactions

Samsara BioCapital GP, LLC10 percent owner1$1.26M0$0$1.26M
McMinn RachelChief Executive Officer1$969,0000$0$969,000
Cvijic Christine MikailPresident and CFO1$491,4001$76,247$415,153

About Neurogene Inc.

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Insider Activity of Neurogene Inc.

Over the last 12 months, insiders at Neurogene Inc. have bought $2.72M and sold $76,247 worth of Neurogene Inc. stock.

On average, over the past 5 years, insiders at Neurogene Inc. have bought $2.72M and sold $76,247 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Samsara BioCapital GP, LLC (10 percent owner) — $1.26M. McMinn Rachel (Chief Executive Officer) — $969,000. Cvijic Christine Mikail (President and CFO) — $491,400.

The last purchase of 48,770 shares for transaction amount of $1.26M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2024‑11‑26.

List of Insider Buy and Sell Transactions, Neurogene Inc.

2025-03-13SaleCvijic Christine MikailPresident and CFO
4,501
0.0216%
$16.94$76,247-0.89%
2024-11-26PurchaseSamsara BioCapital GP, LLC10 percent owner
48,770
0.3334%
$25.83$1.26M-31.22%
2024-11-22PurchaseMcMinn RachelChief Executive Officer
47,500
0.2565%
$20.40$969,000-8.24%
2024-11-22PurchaseCvijic Christine MikailPresident and CFO
24,000
0.1301%
$20.48$491,400-8.24%
Total: 4
*Gray background shows transactions not older than one year

NGNE Institutional Investors: Active Positions

Increased Positions58+60.42%5M+37.37%
Decreased Positions42-43.75%3M-20.97%
New Positions28New946,654New
Sold Out Positions25Sold Out2MSold Out
Total Postitions112+16.67%16M+16.4%

NGNE Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Samsara Biocapital, Llc$28,676.008.18%1.72M+449,337+35.44%2024-12-31
Blackrock, Inc.$25,320.007.22%1.52M+144,278+10.52%2024-12-31
Rtw Investments, Lp$22,549.006.43%1.35M+215,000+18.94%2024-12-31
Redmile Group, Llc$22,040.006.29%1.32M+355,416+36.86%2024-12-31
Casdin Capital, Llc$21,633.006.17%1.3M+770,745+146.92%2024-12-31
Ecor1 Capital, Llc$21,231.006.05%1.27M00%2024-12-31
Fmr Llc$14,368.004.1%860,333+128,532+17.56%2024-12-31
Commodore Capital Lp$13,360.003.81%800,000+600,000+300%2024-12-31
Baker Bros. Advisors Lp$11,263.003.21%674,450+218,435+47.9%2024-12-31
Vanguard Group Inc$9,486.002.71%568,016-8,144-1.41%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.